Eric Zanelli
Research Subjects
Eric Zanelli has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Maria J. de Castro Lopez
Hospital Clínico Universitario de Santiago, University of Santiago de Compostela, IDIS, CIBERER, MetabERN, A Coruña, Spain
2 shared publicationsAdam J. Shaywitz
BioMarin Pharmaceutical, Novato, CA
1 shared publication- Adam J. Shaywitz
10BioMarin Pharmaceutical Inc., Novato, California, USA
1 shared publication Anja Koehn
International Center for Lysosomal Disorders, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publication- Anja Koehn
University Medical Center Hamburg-Eppendorf, International Center for Lysosomal Disorders (ICLD), Hamburg, Germany
1 shared publication Bernice Kuca
Allievex Corporation, Marblehead, MA
1 shared publication
Latest Publications
- Open Access
- 10 July 2024
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 142 (4) , 108535
Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses
- 10 July 2024
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 142 (4) , 108535
Open AccessCommunity consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses
- Open Access
- 17 January 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (2)
A phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B
Background. Sanfilippo type B is a mucopolysaccharidosis (MPS) with a major neuronopathic component characterized by heparan sulfate (HS) accumulation due to mutations in the NAGLU gene encoding alfa-N-acetyl-glucosaminidase. Enzyme replacement therapy for neuronopathic MPS requires efficient enzyme delivery throughout the brain in order to normalize HS levels, prevent brain atrophy, and potentially delay cognitive decline. Methods. In this phase I/II open-label study, patients with MPS type IIIB (n = 22) were treated with tralesinidase alfa administered i.c.v. The patients were monitored for drug exposure; total HS and HS nonreducing end (HS-NRE) levels in both cerebrospinal fluid (CSF) and plasma; anti-drug antibody response; brain, spleen, and liver volumes as measured by MRI; and cognitive development as measured by age-equivalent (AEq) scores. Results. In the Part 1 dose escalation (30, 100, and 300 mg) phase, a 300 mg dose of tralesinidase alfa was necessary to achieve normalization of HS and HS-NRE levels in the CSF and plasma. In Part 2, 300 mg tralesinidase alfa sustained HS and HS-NRE normalization in the CSF and stabilized cortical gray matter volume (CGMV) over 48 weeks of treatment. Resolution of hepatomegaly and a reduction in spleen volume were observed in most patients. Significant correlations were also established between the change in cognitive AEq score and plasma drug exposure, plasma HS-NRE levels, and CGMV. Conclusion. Administration of tralesinidase alfa i.c.v. effectively normalized HS and HS-NRE levels as a prerequisite for clinical efficacy. Peripheral drug exposure data suggest a role for the glymphatic system in altering tralesinidase alfa efficacy. Trial registration. Clinicaltrials.gov NCT02754076. FUNDING. BioMarin Pharmaceutical Inc. and Allievex Corporation.
- 17 January 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (2)
Open AccessA phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B
Background. Sanfilippo type B is a mucopolysaccharidosis (MPS) with a major neuronopathic component characterized by heparan sulfate (HS) accumulation due to mutations in the NAGLU gene encoding alfa-N-acetyl-glucosaminidase. Enzyme replacement therapy for neuronopathic MPS requires efficient enzyme delivery throughout the brain in order to normalize HS levels, prevent brain atrophy, and potentially delay cognitive decline. Methods. In this phase I/II open-label study, patients with MPS type IIIB (n = 22) were treated with tralesinidase alfa administered i.c.v. The patients were monitored for drug exposure; total HS and HS nonreducing end (HS-NRE) levels in both cerebrospinal fluid (CSF) and plasma; anti-drug antibody response; brain, spleen, and liver volumes as measured by MRI; and cognitive development as measured by age-equivalent (AEq) scores. Results. In the Part 1 dose escalation (30, 100, and 300 mg) phase, a 300 mg dose of tralesinidase alfa was necessary to achieve normalization of HS and HS-NRE levels in the CSF and plasma. In Part 2, 300 mg tralesinidase alfa sustained HS and HS-NRE normalization in the CSF and stabilized cortical gray matter volume (CGMV) over 48 weeks of treatment. Resolution of hepatomegaly and a reduction in spleen volume were observed in most patients. Significant correlations were also established between the change in cognitive AEq score and plasma drug exposure, plasma HS-NRE levels, and CGMV. Conclusion. Administration of tralesinidase alfa i.c.v. effectively normalized HS and HS-NRE levels as a prerequisite for clinical efficacy. Peripheral drug exposure data suggest a role for the glymphatic system in altering tralesinidase alfa efficacy. Trial registration. Clinicaltrials.gov NCT02754076. FUNDING. BioMarin Pharmaceutical Inc. and Allievex Corporation.
- Open Access
- 13 June 2022
- Published by Elsevier in The Journal of Pediatrics
- Vol. 249, 50-58.e2
Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB
- 13 June 2022
- Published by Elsevier in The Journal of Pediatrics
- Vol. 249, 50-58.e2
Open AccessLongitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB